Your browser doesn't support javascript.
loading
Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis.
Adhikari, Juthi; Hirai, Taro; Kawakita, Emi; Iwai, Kunimitsu; Koya, Daisuke; Kanasaki, Keizo.
Afiliação
  • Adhikari J; Department of Internal Medicine 1, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.
  • Hirai T; Department of Diabetes and Endocrinology, Kanazawa Medical University, Kahoku District, Ishikawa, Japan.
  • Kawakita E; Department of Internal Medicine 1, Faculty of Medicine, Shimane University, Izumo, Shimane, Japan.
  • Iwai K; Department of Diabetes and Endocrinology, Kanazawa Medical University, Kahoku District, Ishikawa, Japan.
  • Koya D; Health Evaluation Center, Kanazawa Medical University Hospital, Kahoku District, Ishikawa, Japan.
  • Kanasaki K; Department of Diabetes and Endocrinology, Kanazawa Medical University, Kahoku District, Ishikawa, Japan.
J Diabetes Investig ; 14(7): 844-855, 2023 Jul.
Article em En | MEDLINE | ID: mdl-37092329
ABSTRACT
AIMS/

INTRODUCTION:

Linagliptin is a selective dipeptidyl peptidase (DPP)-4 inhibitor capable of successfully regulating blood glucose levels. The cardiovascular protective effects of several DPP-4 inhibitors have been shown in preclinical studies; however, the detailed influence of DPP-4 inhibitors on diabetic pathological alterations in cardiac tissue has not yet been elucidated. MATERIALS AND

METHODS:

We combined laboratory-based experiments and bioinformatics techniques to identify suitable candidate targets with significant biological pathways. Mice with streptozotocin-induced insulin deficiency diabetic model were utilized for in vivo experiments. Mice were euthanized at 24 weeks after the induction of diabetes; linagliptin intervention was carried out for 4 weeks before euthanasia. Microarray analysis of heart samples was carried out.

RESULTS:

Mice with streptozotocin-induced diabetes, but not control mice, showed cardiac fibrosis with an endothelial-mesenchymal transition program, and myocardial fiber and sarcomere disruption; linagliptin alleviated these diabetes-associated pathological alterations without altering blood glucose levels. Bioinformatics analysis utilizing a microarray dataset identified 10 hub genes that were confirmed to have human disease relevance by Gene Expression Omnibus analysis. Among these hub genes, we focused on the Sox9-necroptosis axis as a therapeutic target in diabetic hearts. Indeed, diabetic mice showed the induction of necroptosis-associated genes and the phosphorylation of RIP3 and mixed lineage kinase domain-like protein.

CONCLUSIONS:

Linagliptin showed excellent heart protection in mice with streptozotocin-induced diabetes associated with alterations in human disease-relevant hub genes. Further investigation is required to determine why DPP-4 inhibitors do not show similar superior organ-protective effects in the clinical setting.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Experimental / Inibidores da Dipeptidil Peptidase IV Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Experimental / Inibidores da Dipeptidil Peptidase IV Tipo de estudo: Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article